Empowering Oncology Decisions
DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and lab services that increase clinician and patient confidence in making critical treatment decisions.
Special Announcement
New studies show DiagnoCure’s PCA3 prostate cancer marker can help guide repeat prostate biopsy decisions and predict risk of aggressive cancer
News
- March 8, 2010 - New studies show DiagnoCure’s PCA3 prostate cancer marker can help guide repeat prostate biopsy decisions and predict risk of aggressive cancer
- March 3, 2010 - DiagnoCure to host Q1 2010 Conference call and Webcast
Events
-
May 15 - 19, 2010
2010 ASCRS Annual Meeting
Minneapolis, MN, USA
